Shopping Cart 0
Cart Subtotal
USD 0

Ono Pharmaceutical Co Ltd (4528) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Ono Pharmaceutical Co Ltd (Ono Pharmaceutical) is a focuses on the research, development, manufacture and sale of prescription pharmaceuticals and diagnostic reagents. Its product portfolio includes pharmaceuticals for the treatment of type II diabetes, overactive bladder, osteoporosis, Alzheimer's disease, peripheral circulatory disorder, bronchial asthma and allergic rhinitis, among others. The company offers products in various formulations such as capsules, tablets, injections, patches, dry syrup and intravenous infusion. Ono Pharmaceutical also has products in pipeline development. It offers its products in Americas, Europe and Asia . Ono Pharmaceutical is headquartered in Chuo-ku, Osaka, Japan.

Ono Pharmaceutical Co Ltd (4528)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 7

List of Figures 7

Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 9

Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 10

Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 11

Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 12

Ono Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 14

Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 15

Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deal Details 18

Partnerships 18

Fate Therapeutics Enters into Agreement with ONO Pharma 18

Ono Pharma Enters into Research Agreement with Schrodinger 19

Cyclenium Pharma Enters into Agreement with Ono Pharma 20

Neurimmune Therapeutics Enters into Co-Development Agreement with Ono Pharma 21

Ono Pharma Enters into Agreement with Eisai 22

Ono Pharma and Seikagaku Enter into Co-Development Agreement 23

Numab Therapeutics Enters into Research and Option Agreement with Ono Pharma 24

X-Chem Enters into Agreement with Ono Pharma 25

Takeda Pharma and Shionogi Enter into Research Agreement with Sumitomo Dainippon Pharma, Ono Pharma and Mitsubishi Tanabe Pharma 26

Astellas Pharm, Kyowa Hakko Kirin, Daiichi Sankyo, Eisai, Ono Pharma and Chugai Pharma to Enter into Agreemet with Four Research Institutions 28

Ono Pharma Enters into Development Agreement with China Chemical & Pharma for Limaprost Alfadex 30

Dako Enters into Development Agreement with ONO PHARMA for Opdivo 31

Ono Pharma Enters into Development Agreement with Meiji Seika for Limaprost Alfadex 32

Bristol-Myers Squibb Enters into Co-Development Agreement with Ono Pharma 33

AstraZeneca Enters Into Co-Promotion Agreement With Ono Pharma For Dapagliflozin 35

Ono Pharma Expands Co -Development Agreement With Dainippon Sumitomo Pharma For Limaprost Alfadex 36

Ono Pharma Enters Into Drug Discovery Agreement With Domain Therapeutics 37

Ono Pharma Enters Into Discovery Agreement With BioFocus For CNS Drugs 38

Ono Pharma Enters Into Drug Discovery Agreement With BioFocus 39

Ono Pharma Enters Into Co-Development Agreement With Scil Proteins For Affilin Therapeutics 40

Licensing Agreements 41

Ono Pharma Enters into Licensing Agreement with Merus 41

Bristol-Myers Squibb Enters into Licensing Agreement with Ono Pharma for ONO-4578 42

ONO Pharma Enters into Licensing Agreement with Karyopharm Therapeutics 43

Ono Pharma Enters into Licensing Agreement with Array BioPharma 44

Merck Enters into Licensing Agreement with Bristol-Myers Squibb and Ono Pharma 45

Ono Pharma Enters into Licensing Agreement with Ligand Pharma 47

ONO Pharma Enters into Licensing Agreement with Celyad 48

ONO Pharma Enters into Licensing Agreement with IDAC Theranostics 49

Santen Pharma Enters into Licensing Agreement with Ono Pharma 50

Ono Pharma Enters into Licensing Agreement with Gilead Sciences for ONO-4059 51

Ono Pharma Exercises Option for Licensing Agreement with with Merus 52

Ono Pharma Enters into Licensing Agreement with Valeant Pharma 53

Ono Pharma Enters Into Licensing Agreement With Bial For BIA 9-1067 54

Ono Pharma Enters Into Licensing Agreement With Genedata For Genedata Expressionist 55

Asset Transactions 56

Maruishi Pharma to Acquire Five Injectable Brands from Ono Pharma 56

Ono Pharmaceutical Co Ltd-Key Competitors 57

Ono Pharmaceutical Co Ltd-Key Employees 58

Ono Pharmaceutical Co Ltd-Locations And Subsidiaries 59

Head Office 59

Other Locations & Subsidiaries 59

Recent Developments 61

Strategy And Business Planning 61

Mar 01, 2018: Ono Pharmaceutical Announce Completion of a New Tokyo Building 61

Corporate Communications 62

Jul 13, 2018: Ono Pharmaceutical: Support for the Torrential rain damage in Western Japan 62

Apr 05, 2018: Ono Pharmaceutical Announce on Candidates of Members of the Board of Directors and Corporate Officers 63

Government and Public Interest 64

May 30, 2018: Notice Regarding Establishment of Immune-mediated Inflammatory Diseases Consortium for Drug Development 64

Product News 65

11/30/2017: Cancer drug leads to drastic decrease in HIV infection in lung cancer patient 65

11/15/2017: LabCorp Announces New Expanded Use for PD-L1 Test with Bristol-Myers Squibb's OPDIVO 67

11/10/2017: Encouraging Response Observed with Opdivo (nivolumab) Plus Investigational IDO1 Inhibitor, BMS-986205, in Heavily Pre-Treated Patients with Advanced Cancers in Phase 1/2a Study CA017-003 68

11/07/2017: Opdivo (Nivolumab) Intravenous Infusion Approved in Taiwan for Expanded Use in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated with Platinum-based Therapy 70

10/30/2017: Opdivo (Nivolumab) Intravenous Infusion Approved in Taiwan for Additional Indications of Relapsed or Progressed Classical Hodgkin Lymphoma, Locally Advanced Unresectable or Metastatic Urothelial Carcinoma, and Unresectable or Metastatic Melanoma 71

09/22/2017: Bristol-Myers Squibb's Opdivo Receives FDA Approval for the Treatment of Hepatocellular Carcinoma Patients Previously Treated with Sorafenib 72

09/22/2017: Japan Ministry of Health, Labor and Welfare Approves Opdivo (nivolumab) for the Treatment of Patients with Unresectable Advanced or Recurrent Gastric Cancer Which Has Progressed After Chemotherapy 74

09/21/2017: Promising immunotherapy drug now available for some lung cancer patients in England 76

09/20/2017: Opdivo (Nivolumab) Intravenous Infusion Approved for Expanded Use in Advanced Non-squamous Non-small Cell Lung Cancer which Has Been Previously Treated with Platinum-based Therapy in Taiwan 77

09/20/2017: Nivolumab now available for lung cancer after company offers NICE new CDF deal 78

09/19/2017: Opdivo (Nivolumab) Intravenous Infusion Approved for Expanded Use in Unresectable or Metastatic Melanoma in South Korea 79

08/30/2017: Opdivo (Nivolumab) Intravenous Infusion Approved for Supplemental Indications of Advanced Renal Cell Carcinoma, Relapsed or Progressed Classical Hodgkin Lymphoma, Recurrent or Metastatic Head and Neck, Locally Advanced or Metastatic Urothelial Carcinoma, and Unresectable or Metastatic Melanoma in Combination with Ipilimumab in South Korea 80

08/16/2017: Opdivo Intravenous Infusion Approved for Supplemental Indication of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck with Disease Progression on or after Platinum-based Therapy in Taiwan 81

08/11/2017: FDA Approves Updated Indication for Opdivo (nivolumab) 82

08/01/2017: Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab) in MSI-H or dMMR Metastatic Colorectal Cancer That Has Progressed Following Treatment with a Fluoropyrimidine, Oxaliplatin, and Irinotecan 83

06/02/2017: NICE approves first use of Opdivo (nivolumab) in blood cancer 84

05/17/2017: Health Canada approves OPDIVO (nivolumab) for the treatment of squamous cell carcinoma of the head and neck 85

05/05/2017: White Blood Cell Count Predicts Response to Lung Cancer Immunotherapy 86

04/28/2017: European Commission Approves Bristol-Myers Squibb's Opdivo (nivolumab) for Squamous Cell Cancer of the Head and Neck in Adults Progressing On or After Platinum-based Therapy 87

04/24/2017: Opdivo (nivolumab) Designated for the Treatment of Biliary Tract Cancer Under the SAKIGAKE Designation System 89

04/21/2017: CHMP Adopts Extension To Existing Therapeutic Indication For Opdivo 90

04/21/2017: Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo (nivolumab) for the Treatment of Patients with Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma, a Type of Bladder Cancer 91

04/03/2017: Patients with Lung Cancers Responsive to Immunotherapy Drug Beat Standard Odds of Survival 92

03/24/2017: Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Opdivo (nivolumab) for the Treatment of Squamous Cell Cancer of the Head and Neck in Adults Progressing on or After Platinum-based Therapy 94

03/24/2017: ONO Receives Approval for OPDIVO (Nivolumab) Intravenous Infusion for Treatment of Recurrent or Metastatic Head and Neck Cancer as a Partial Change in Approved Items of Manufacturing and Marketing Approval in Japan 95

03/22/2017: Ontario Latest Province to Cover Cost of Immuno-Oncology Treatment OPDIVO (nivolumab) 96

03/15/2017: Manitoba to Cover Immuno-Oncology Treatment OPDIVO (nivolumab) for Three Tumour Types 97

03/02/2017: British Columbia to Cover Immuno-Oncology Treatment OPDIVO (nivolumab) for Three Tumour Types 98

02/02/2017: Bristol-Myers Squibb Company Received Approval for Nivolumab by U.S. Food and Drug Administration for Treatment of Urothelial Carcinoma 99

Product Approvals 100

Jul 30, 2018: ONO submits supplemental application of ONOACT for intravenous infusion 50mg150mg, short-acting selective 1 blocker for indication of ventricular arrhythmia for a partial change in approved items of manufacturing and marketing approval in Japan 100

Oct 30, 2017: European Medicines Agency Validates Bristol-Myers Squibbs Type II Variation Application for Opdivo (nivolumab) for Treatment of Patients with Resected High-Risk Advanced Melanoma 101

Oct 16, 2017: U.S. Food and Drug Administration Accepts Bristol-Myers Squibb's Application for Opdivo (nivolumab) in Patients with Resected High-Risk Advanced Melanoma and Grants Priority Review 102

Sep 21, 2017: Withdrawal of the Application for a Change to the Marketing Authorisation for Nivolumab in EU 103

Sep 15, 2017: Withdrawal of the application for a change to the marketing authorisation for Opdivo (nivolumab) 104

Sep 11, 2017: Opdivo is accepted for restricted use within NHS Scotland 105

Jul 24, 2017: U.S. Food and Drug Administration Accepts Bristol-Myers Squibbs Applications for Opdivo (nivolumab) Four-Week Dosing Schedule Across All Approved Indications 106

Jul 10, 2017: SMC says yes' to Opdivo (nivolumab) for blood cancer patients 107

Jun 12, 2017: SMC U-turn' brings breakthrough immunotherapy Opdivo (nivolumab) to kidney cancer patients 108

Jun 02, 2017: European Commission Approves Bristol-Myers Squibb's Opdivo (nivolumab) for Previously Treated Locally Advanced Unresectable or Metastatic Urothelial Carcinoma in Adults After Failure of Prior Platinum-Containing Therapy 109

May 24, 2017: U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb's Application for Opdivo (nivolumab) in Previously Treated Hepatocellular Carcinoma 111

Apr 04, 2017: U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb's Application for Opdivo (nivolumab) in Previously Treated dMMR or MSI-H Metastatic Colorectal Cancer 112

Clinical Trials 113

Dec 05, 2017: U.S. Food and Drug Administration Lifts Partial Clinical Holds on Two Opdivo-based Combination Studies in Multiple Myeloma 113

Nov 30, 2017: CheckMate -078, a Pivotal, Multinational Phase 3 Opdivo (nivolumab) Lung Cancer Trial with Predominantly Chinese Patients, Stopped Early for Demonstrating Superior Overall Survival 114

Nov 29, 2017: Bristol-Myers Squibb to Present Clinical Trial Data of Antineoplastic Agent Nivolumab at the 59th Annual Meeting & Exposition of the American Society of Hematology 115

Nov 06, 2017: Opdivo (nivolumab) Demonstrates Superior Three-Year Survival Benefit for Patients with Previously Treated Advanced Renal Cell Carcinoma 117

Oct 25, 2017: New Investigator Led Study Examining the Combination of SIR-Spheres Y-90 Resin Microspheres with Opdivo in HCC 118

Oct 13, 2017: NICE U-turn recommends head and neck cancer medicine which offers biggest increase in survival for 20 years 119

Oct 12, 2017: Stand Up To Cancer Awards Moffitt $2.67 Million to Study New Lung Cancer Immunotherapy 120

Sep 27, 2017: Bristol-Myers Squibb: Advancing Research Across Thoracic Cancers with New Data at IASLC 18th World Conference on Lung Cancer 121

Sep 10, 2017: Opdivo (nivolumab) Demonstrates Superior Recurrence-Free Survival Versus Yervoy (ipilimumab) for Patients with Resected High-Risk Melanoma in Phase 3 CheckMate -238 Study 124

Sep 08, 2017: Two Pivotal Opdivo (nivolumab) Trials Show Three-Year Survival Benefit in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer 126

Sep 06, 2017: Bristol-Myers Squibb Provides an Update on Three Opdivo-based Combination Clinical Studies in Multiple Myeloma 128

Aug 30, 2017: Bristol-Myers Squibb Data at ESMO 2017 Demonstrate Company's Innovative Research Approach to Treating Cancer from All Angles 129

Jul 10, 2017: Exelixis and Bristol-Myers Squibb Initiate Phase 3 Trial of Opdivo in Combination with CABOMETYX or Opdivo and Yervoy in Combination with CABOMETYX, Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma 135

Jul 05, 2017: Phase 3 Study Evaluating the Safety and Efficacy of Adjuvant Opdivo in Resected High-Risk Melanoma Patients Meets Primary Endpoint 136

Jun 21, 2017: First-line immunotherapy treatment can improve survival for subset of lung cancer patients 137

Jun 16, 2017: Extended Follow-Up Data Evaluating Opdivo (nivolumab) Shows Durable Response in Adult Patients with Relapsed or Progressed Classical Hodgkin Lymphoma 138

Jun 05, 2017: Encouraging Disease Control Rates Observed with Nivolumab Alone or in Combination with Ipilimumab in Refractory or Relapsing Malignant Pleural Mesothelioma Patients: Results from IFCT-1501 MAPS-2 Trial 139

Jun 02, 2017: Opdivo (nivolumab) Data in Patients with Advanced Cervical, Vaginal and Vulvar Cancers from Phase 1/2 CheckMate -358 Presented at ASCO 140

May 18, 2017: New trial to fight cancer caused by asbestos 142

Apr 11, 2017: Head and neck cancer patients set to miss out on first medicine to show biggest increase in survival for 20 years 144

Apr 04, 2017: Unprecedented 5-year follow-up shows long-term survival in lung cancer 145

Apr 03, 2017: Bristol-Myers Squibb Announces Results from CheckMate -143, a Phase 3 Study of Opdivo (nivolumab) in Patients with Glioblastoma Multiforme 147

Apr 03, 2017: Five-Year Survival Observed With Opdivo (nivolumab) in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer, in Phase 1 Study CA209-003 148

Apr 03, 2017: Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) and Opdivo Monotherapy Significantly Improved Overall Survival Versus Yervoy Alone in Patients with Previously Untreated Advanced Melanoma 150

Apr 02, 2017: Bristol-Myers Squibb and Incyte to Advance the Combination of Opdivo (nivolumab) and Epacadostat into First-line Registrational Trials 152

Jan 19, 2017: Opdivo (nivolumab) Demonstrated Efficacy and Improved Survival in Patients with Previously Treated Advanced Gastric Cancer in a Randomized Phase 3 Study 153

Appendix 155

Methodology 155

About GlobalData 155

Contact Us 155

Disclaimer 155


List Of Figure

List of Figures

Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 9

Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 10

Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 11

Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 12

Ono Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 14


List Of Table

List of Tables

Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 9

Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 10

Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 11

Ono Pharmaceutical Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 12

Ono Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 14

Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 15

Fate Therapeutics Enters into Agreement with ONO Pharma 18

Ono Pharma Enters into Research Agreement with Schrodinger 19

Cyclenium Pharma Enters into Agreement with Ono Pharma 20

Neurimmune Therapeutics Enters into Co-Development Agreement with Ono Pharma 21

Ono Pharma Enters into Agreement with Eisai 22

Ono Pharma and Seikagaku Enter into Co-Development Agreement 23

Numab Therapeutics Enters into Research and Option Agreement with Ono Pharma 24

X-Chem Enters into Agreement with Ono Pharma 25

Takeda Pharma and Shionogi Enter into Research Agreement with Sumitomo Dainippon Pharma, Ono Pharma and Mitsubishi Tanabe Pharma 26

Astellas Pharm, Kyowa Hakko Kirin, Daiichi Sankyo, Eisai, Ono Pharma and Chugai Pharma to Enter into Agreemet with Four Research Institutions 28

Ono Pharma Enters into Development Agreement with China Chemical & Pharma for Limaprost Alfadex 30

Dako Enters into Development Agreement with ONO PHARMA for Opdivo 31

Ono Pharma Enters into Development Agreement with Meiji Seika for Limaprost Alfadex 32

Bristol-Myers Squibb Enters into Co-Development Agreement with Ono Pharma 33

AstraZeneca Enters Into Co-Promotion Agreement With Ono Pharma For Dapagliflozin 35

Ono Pharma Expands Co -Development Agreement With Dainippon Sumitomo Pharma For Limaprost Alfadex 36

Ono Pharma Enters Into Drug Discovery Agreement With Domain Therapeutics 37

Ono Pharma Enters Into Discovery Agreement With BioFocus For CNS Drugs 38

Ono Pharma Enters Into Drug Discovery Agreement With BioFocus 39

Ono Pharma Enters Into Co-Development Agreement With Scil Proteins For Affilin Therapeutics 40

Ono Pharma Enters into Licensing Agreement with Merus 41

Bristol-Myers Squibb Enters into Licensing Agreement with Ono Pharma for ONO-4578 42

ONO Pharma Enters into Licensing Agreement with Karyopharm Therapeutics 43

Ono Pharma Enters into Licensing Agreement with Array BioPharma 44

Merck Enters into Licensing Agreement with Bristol-Myers Squibb and Ono Pharma 45

Ono Pharma Enters into Licensing Agreement with Ligand Pharma 47

ONO Pharma Enters into Licensing Agreement with Celyad 48

ONO Pharma Enters into Licensing Agreement with IDAC Theranostics 49

Santen Pharma Enters into Licensing Agreement with Ono Pharma 50

Ono Pharma Enters into Licensing Agreement with Gilead Sciences for ONO-4059 51

Ono Pharma Exercises Option for Licensing Agreement with with Merus 52

Ono Pharma Enters into Licensing Agreement with Valeant Pharma 53

Ono Pharma Enters Into Licensing Agreement With Bial For BIA 9-1067 54

Ono Pharma Enters Into Licensing Agreement With Genedata For Genedata Expressionist 55

Maruishi Pharma to Acquire Five Injectable Brands from Ono Pharma 56

Ono Pharmaceutical Co Ltd, Key Competitors 57

Ono Pharmaceutical Co Ltd, Key Employees 58

Ono Pharmaceutical Co Ltd, Other Locations 59

Ono Pharmaceutical Co Ltd, Subsidiaries 60

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Ono Pharmaceutical Co Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Ono Pharmaceutical Co Ltd (Ono Pharmaceutical) is a focuses on the research, development, manufacture and sale of prescription pharmaceuticals and diagnostic reagents. Its product portfolio includes pharmaceuticals for the treatment of type II diabetes, overactive bladder, osteoporosis, Alzheimer's disease, peripheral circulatory disorder, bronchial asthma and allergic rhinitis, among others. The company offers products in various formulations such as capsules, tablets, injections, patches, dry syrup and intravenous infusion. Ono Pharmaceutical also has products in pipeline development. It offers its products in Americas, Europe and Asia . Ono Pharmaceutical is headquartered in Chuo-ku, Osaka, Japan.

Ono Pharmaceutical Co Ltd (4528)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 7

List of Figures 7

Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 9

Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 10

Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 11

Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 12

Ono Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 14

Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 15

Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deal Details 18

Partnerships 18

Fate Therapeutics Enters into Agreement with ONO Pharma 18

Ono Pharma Enters into Research Agreement with Schrodinger 19

Cyclenium Pharma Enters into Agreement with Ono Pharma 20

Neurimmune Therapeutics Enters into Co-Development Agreement with Ono Pharma 21

Ono Pharma Enters into Agreement with Eisai 22

Ono Pharma and Seikagaku Enter into Co-Development Agreement 23

Numab Therapeutics Enters into Research and Option Agreement with Ono Pharma 24

X-Chem Enters into Agreement with Ono Pharma 25

Takeda Pharma and Shionogi Enter into Research Agreement with Sumitomo Dainippon Pharma, Ono Pharma and Mitsubishi Tanabe Pharma 26

Astellas Pharm, Kyowa Hakko Kirin, Daiichi Sankyo, Eisai, Ono Pharma and Chugai Pharma to Enter into Agreemet with Four Research Institutions 28

Ono Pharma Enters into Development Agreement with China Chemical & Pharma for Limaprost Alfadex 30

Dako Enters into Development Agreement with ONO PHARMA for Opdivo 31

Ono Pharma Enters into Development Agreement with Meiji Seika for Limaprost Alfadex 32

Bristol-Myers Squibb Enters into Co-Development Agreement with Ono Pharma 33

AstraZeneca Enters Into Co-Promotion Agreement With Ono Pharma For Dapagliflozin 35

Ono Pharma Expands Co -Development Agreement With Dainippon Sumitomo Pharma For Limaprost Alfadex 36

Ono Pharma Enters Into Drug Discovery Agreement With Domain Therapeutics 37

Ono Pharma Enters Into Discovery Agreement With BioFocus For CNS Drugs 38

Ono Pharma Enters Into Drug Discovery Agreement With BioFocus 39

Ono Pharma Enters Into Co-Development Agreement With Scil Proteins For Affilin Therapeutics 40

Licensing Agreements 41

Ono Pharma Enters into Licensing Agreement with Merus 41

Bristol-Myers Squibb Enters into Licensing Agreement with Ono Pharma for ONO-4578 42

ONO Pharma Enters into Licensing Agreement with Karyopharm Therapeutics 43

Ono Pharma Enters into Licensing Agreement with Array BioPharma 44

Merck Enters into Licensing Agreement with Bristol-Myers Squibb and Ono Pharma 45

Ono Pharma Enters into Licensing Agreement with Ligand Pharma 47

ONO Pharma Enters into Licensing Agreement with Celyad 48

ONO Pharma Enters into Licensing Agreement with IDAC Theranostics 49

Santen Pharma Enters into Licensing Agreement with Ono Pharma 50

Ono Pharma Enters into Licensing Agreement with Gilead Sciences for ONO-4059 51

Ono Pharma Exercises Option for Licensing Agreement with with Merus 52

Ono Pharma Enters into Licensing Agreement with Valeant Pharma 53

Ono Pharma Enters Into Licensing Agreement With Bial For BIA 9-1067 54

Ono Pharma Enters Into Licensing Agreement With Genedata For Genedata Expressionist 55

Asset Transactions 56

Maruishi Pharma to Acquire Five Injectable Brands from Ono Pharma 56

Ono Pharmaceutical Co Ltd-Key Competitors 57

Ono Pharmaceutical Co Ltd-Key Employees 58

Ono Pharmaceutical Co Ltd-Locations And Subsidiaries 59

Head Office 59

Other Locations & Subsidiaries 59

Recent Developments 61

Strategy And Business Planning 61

Mar 01, 2018: Ono Pharmaceutical Announce Completion of a New Tokyo Building 61

Corporate Communications 62

Jul 13, 2018: Ono Pharmaceutical: Support for the Torrential rain damage in Western Japan 62

Apr 05, 2018: Ono Pharmaceutical Announce on Candidates of Members of the Board of Directors and Corporate Officers 63

Government and Public Interest 64

May 30, 2018: Notice Regarding Establishment of Immune-mediated Inflammatory Diseases Consortium for Drug Development 64

Product News 65

11/30/2017: Cancer drug leads to drastic decrease in HIV infection in lung cancer patient 65

11/15/2017: LabCorp Announces New Expanded Use for PD-L1 Test with Bristol-Myers Squibb's OPDIVO 67

11/10/2017: Encouraging Response Observed with Opdivo (nivolumab) Plus Investigational IDO1 Inhibitor, BMS-986205, in Heavily Pre-Treated Patients with Advanced Cancers in Phase 1/2a Study CA017-003 68

11/07/2017: Opdivo (Nivolumab) Intravenous Infusion Approved in Taiwan for Expanded Use in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated with Platinum-based Therapy 70

10/30/2017: Opdivo (Nivolumab) Intravenous Infusion Approved in Taiwan for Additional Indications of Relapsed or Progressed Classical Hodgkin Lymphoma, Locally Advanced Unresectable or Metastatic Urothelial Carcinoma, and Unresectable or Metastatic Melanoma 71

09/22/2017: Bristol-Myers Squibb's Opdivo Receives FDA Approval for the Treatment of Hepatocellular Carcinoma Patients Previously Treated with Sorafenib 72

09/22/2017: Japan Ministry of Health, Labor and Welfare Approves Opdivo (nivolumab) for the Treatment of Patients with Unresectable Advanced or Recurrent Gastric Cancer Which Has Progressed After Chemotherapy 74

09/21/2017: Promising immunotherapy drug now available for some lung cancer patients in England 76

09/20/2017: Opdivo (Nivolumab) Intravenous Infusion Approved for Expanded Use in Advanced Non-squamous Non-small Cell Lung Cancer which Has Been Previously Treated with Platinum-based Therapy in Taiwan 77

09/20/2017: Nivolumab now available for lung cancer after company offers NICE new CDF deal 78

09/19/2017: Opdivo (Nivolumab) Intravenous Infusion Approved for Expanded Use in Unresectable or Metastatic Melanoma in South Korea 79

08/30/2017: Opdivo (Nivolumab) Intravenous Infusion Approved for Supplemental Indications of Advanced Renal Cell Carcinoma, Relapsed or Progressed Classical Hodgkin Lymphoma, Recurrent or Metastatic Head and Neck, Locally Advanced or Metastatic Urothelial Carcinoma, and Unresectable or Metastatic Melanoma in Combination with Ipilimumab in South Korea 80

08/16/2017: Opdivo Intravenous Infusion Approved for Supplemental Indication of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck with Disease Progression on or after Platinum-based Therapy in Taiwan 81

08/11/2017: FDA Approves Updated Indication for Opdivo (nivolumab) 82

08/01/2017: Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab) in MSI-H or dMMR Metastatic Colorectal Cancer That Has Progressed Following Treatment with a Fluoropyrimidine, Oxaliplatin, and Irinotecan 83

06/02/2017: NICE approves first use of Opdivo (nivolumab) in blood cancer 84

05/17/2017: Health Canada approves OPDIVO (nivolumab) for the treatment of squamous cell carcinoma of the head and neck 85

05/05/2017: White Blood Cell Count Predicts Response to Lung Cancer Immunotherapy 86

04/28/2017: European Commission Approves Bristol-Myers Squibb's Opdivo (nivolumab) for Squamous Cell Cancer of the Head and Neck in Adults Progressing On or After Platinum-based Therapy 87

04/24/2017: Opdivo (nivolumab) Designated for the Treatment of Biliary Tract Cancer Under the SAKIGAKE Designation System 89

04/21/2017: CHMP Adopts Extension To Existing Therapeutic Indication For Opdivo 90

04/21/2017: Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo (nivolumab) for the Treatment of Patients with Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma, a Type of Bladder Cancer 91

04/03/2017: Patients with Lung Cancers Responsive to Immunotherapy Drug Beat Standard Odds of Survival 92

03/24/2017: Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Opdivo (nivolumab) for the Treatment of Squamous Cell Cancer of the Head and Neck in Adults Progressing on or After Platinum-based Therapy 94

03/24/2017: ONO Receives Approval for OPDIVO (Nivolumab) Intravenous Infusion for Treatment of Recurrent or Metastatic Head and Neck Cancer as a Partial Change in Approved Items of Manufacturing and Marketing Approval in Japan 95

03/22/2017: Ontario Latest Province to Cover Cost of Immuno-Oncology Treatment OPDIVO (nivolumab) 96

03/15/2017: Manitoba to Cover Immuno-Oncology Treatment OPDIVO (nivolumab) for Three Tumour Types 97

03/02/2017: British Columbia to Cover Immuno-Oncology Treatment OPDIVO (nivolumab) for Three Tumour Types 98

02/02/2017: Bristol-Myers Squibb Company Received Approval for Nivolumab by U.S. Food and Drug Administration for Treatment of Urothelial Carcinoma 99

Product Approvals 100

Jul 30, 2018: ONO submits supplemental application of ONOACT for intravenous infusion 50mg150mg, short-acting selective 1 blocker for indication of ventricular arrhythmia for a partial change in approved items of manufacturing and marketing approval in Japan 100

Oct 30, 2017: European Medicines Agency Validates Bristol-Myers Squibbs Type II Variation Application for Opdivo (nivolumab) for Treatment of Patients with Resected High-Risk Advanced Melanoma 101

Oct 16, 2017: U.S. Food and Drug Administration Accepts Bristol-Myers Squibb's Application for Opdivo (nivolumab) in Patients with Resected High-Risk Advanced Melanoma and Grants Priority Review 102

Sep 21, 2017: Withdrawal of the Application for a Change to the Marketing Authorisation for Nivolumab in EU 103

Sep 15, 2017: Withdrawal of the application for a change to the marketing authorisation for Opdivo (nivolumab) 104

Sep 11, 2017: Opdivo is accepted for restricted use within NHS Scotland 105

Jul 24, 2017: U.S. Food and Drug Administration Accepts Bristol-Myers Squibbs Applications for Opdivo (nivolumab) Four-Week Dosing Schedule Across All Approved Indications 106

Jul 10, 2017: SMC says yes' to Opdivo (nivolumab) for blood cancer patients 107

Jun 12, 2017: SMC U-turn' brings breakthrough immunotherapy Opdivo (nivolumab) to kidney cancer patients 108

Jun 02, 2017: European Commission Approves Bristol-Myers Squibb's Opdivo (nivolumab) for Previously Treated Locally Advanced Unresectable or Metastatic Urothelial Carcinoma in Adults After Failure of Prior Platinum-Containing Therapy 109

May 24, 2017: U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb's Application for Opdivo (nivolumab) in Previously Treated Hepatocellular Carcinoma 111

Apr 04, 2017: U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb's Application for Opdivo (nivolumab) in Previously Treated dMMR or MSI-H Metastatic Colorectal Cancer 112

Clinical Trials 113

Dec 05, 2017: U.S. Food and Drug Administration Lifts Partial Clinical Holds on Two Opdivo-based Combination Studies in Multiple Myeloma 113

Nov 30, 2017: CheckMate -078, a Pivotal, Multinational Phase 3 Opdivo (nivolumab) Lung Cancer Trial with Predominantly Chinese Patients, Stopped Early for Demonstrating Superior Overall Survival 114

Nov 29, 2017: Bristol-Myers Squibb to Present Clinical Trial Data of Antineoplastic Agent Nivolumab at the 59th Annual Meeting & Exposition of the American Society of Hematology 115

Nov 06, 2017: Opdivo (nivolumab) Demonstrates Superior Three-Year Survival Benefit for Patients with Previously Treated Advanced Renal Cell Carcinoma 117

Oct 25, 2017: New Investigator Led Study Examining the Combination of SIR-Spheres Y-90 Resin Microspheres with Opdivo in HCC 118

Oct 13, 2017: NICE U-turn recommends head and neck cancer medicine which offers biggest increase in survival for 20 years 119

Oct 12, 2017: Stand Up To Cancer Awards Moffitt $2.67 Million to Study New Lung Cancer Immunotherapy 120

Sep 27, 2017: Bristol-Myers Squibb: Advancing Research Across Thoracic Cancers with New Data at IASLC 18th World Conference on Lung Cancer 121

Sep 10, 2017: Opdivo (nivolumab) Demonstrates Superior Recurrence-Free Survival Versus Yervoy (ipilimumab) for Patients with Resected High-Risk Melanoma in Phase 3 CheckMate -238 Study 124

Sep 08, 2017: Two Pivotal Opdivo (nivolumab) Trials Show Three-Year Survival Benefit in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer 126

Sep 06, 2017: Bristol-Myers Squibb Provides an Update on Three Opdivo-based Combination Clinical Studies in Multiple Myeloma 128

Aug 30, 2017: Bristol-Myers Squibb Data at ESMO 2017 Demonstrate Company's Innovative Research Approach to Treating Cancer from All Angles 129

Jul 10, 2017: Exelixis and Bristol-Myers Squibb Initiate Phase 3 Trial of Opdivo in Combination with CABOMETYX or Opdivo and Yervoy in Combination with CABOMETYX, Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma 135

Jul 05, 2017: Phase 3 Study Evaluating the Safety and Efficacy of Adjuvant Opdivo in Resected High-Risk Melanoma Patients Meets Primary Endpoint 136

Jun 21, 2017: First-line immunotherapy treatment can improve survival for subset of lung cancer patients 137

Jun 16, 2017: Extended Follow-Up Data Evaluating Opdivo (nivolumab) Shows Durable Response in Adult Patients with Relapsed or Progressed Classical Hodgkin Lymphoma 138

Jun 05, 2017: Encouraging Disease Control Rates Observed with Nivolumab Alone or in Combination with Ipilimumab in Refractory or Relapsing Malignant Pleural Mesothelioma Patients: Results from IFCT-1501 MAPS-2 Trial 139

Jun 02, 2017: Opdivo (nivolumab) Data in Patients with Advanced Cervical, Vaginal and Vulvar Cancers from Phase 1/2 CheckMate -358 Presented at ASCO 140

May 18, 2017: New trial to fight cancer caused by asbestos 142

Apr 11, 2017: Head and neck cancer patients set to miss out on first medicine to show biggest increase in survival for 20 years 144

Apr 04, 2017: Unprecedented 5-year follow-up shows long-term survival in lung cancer 145

Apr 03, 2017: Bristol-Myers Squibb Announces Results from CheckMate -143, a Phase 3 Study of Opdivo (nivolumab) in Patients with Glioblastoma Multiforme 147

Apr 03, 2017: Five-Year Survival Observed With Opdivo (nivolumab) in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer, in Phase 1 Study CA209-003 148

Apr 03, 2017: Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) and Opdivo Monotherapy Significantly Improved Overall Survival Versus Yervoy Alone in Patients with Previously Untreated Advanced Melanoma 150

Apr 02, 2017: Bristol-Myers Squibb and Incyte to Advance the Combination of Opdivo (nivolumab) and Epacadostat into First-line Registrational Trials 152

Jan 19, 2017: Opdivo (nivolumab) Demonstrated Efficacy and Improved Survival in Patients with Previously Treated Advanced Gastric Cancer in a Randomized Phase 3 Study 153

Appendix 155

Methodology 155

About GlobalData 155

Contact Us 155

Disclaimer 155


List Of Figure

List of Figures

Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 9

Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 10

Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 11

Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 12

Ono Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 14


List Of Table

List of Tables

Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 9

Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 10

Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 11

Ono Pharmaceutical Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 12

Ono Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 14

Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 15

Fate Therapeutics Enters into Agreement with ONO Pharma 18

Ono Pharma Enters into Research Agreement with Schrodinger 19

Cyclenium Pharma Enters into Agreement with Ono Pharma 20

Neurimmune Therapeutics Enters into Co-Development Agreement with Ono Pharma 21

Ono Pharma Enters into Agreement with Eisai 22

Ono Pharma and Seikagaku Enter into Co-Development Agreement 23

Numab Therapeutics Enters into Research and Option Agreement with Ono Pharma 24

X-Chem Enters into Agreement with Ono Pharma 25

Takeda Pharma and Shionogi Enter into Research Agreement with Sumitomo Dainippon Pharma, Ono Pharma and Mitsubishi Tanabe Pharma 26

Astellas Pharm, Kyowa Hakko Kirin, Daiichi Sankyo, Eisai, Ono Pharma and Chugai Pharma to Enter into Agreemet with Four Research Institutions 28

Ono Pharma Enters into Development Agreement with China Chemical & Pharma for Limaprost Alfadex 30

Dako Enters into Development Agreement with ONO PHARMA for Opdivo 31

Ono Pharma Enters into Development Agreement with Meiji Seika for Limaprost Alfadex 32

Bristol-Myers Squibb Enters into Co-Development Agreement with Ono Pharma 33

AstraZeneca Enters Into Co-Promotion Agreement With Ono Pharma For Dapagliflozin 35

Ono Pharma Expands Co -Development Agreement With Dainippon Sumitomo Pharma For Limaprost Alfadex 36

Ono Pharma Enters Into Drug Discovery Agreement With Domain Therapeutics 37

Ono Pharma Enters Into Discovery Agreement With BioFocus For CNS Drugs 38

Ono Pharma Enters Into Drug Discovery Agreement With BioFocus 39

Ono Pharma Enters Into Co-Development Agreement With Scil Proteins For Affilin Therapeutics 40

Ono Pharma Enters into Licensing Agreement with Merus 41

Bristol-Myers Squibb Enters into Licensing Agreement with Ono Pharma for ONO-4578 42

ONO Pharma Enters into Licensing Agreement with Karyopharm Therapeutics 43

Ono Pharma Enters into Licensing Agreement with Array BioPharma 44

Merck Enters into Licensing Agreement with Bristol-Myers Squibb and Ono Pharma 45

Ono Pharma Enters into Licensing Agreement with Ligand Pharma 47

ONO Pharma Enters into Licensing Agreement with Celyad 48

ONO Pharma Enters into Licensing Agreement with IDAC Theranostics 49

Santen Pharma Enters into Licensing Agreement with Ono Pharma 50

Ono Pharma Enters into Licensing Agreement with Gilead Sciences for ONO-4059 51

Ono Pharma Exercises Option for Licensing Agreement with with Merus 52

Ono Pharma Enters into Licensing Agreement with Valeant Pharma 53

Ono Pharma Enters Into Licensing Agreement With Bial For BIA 9-1067 54

Ono Pharma Enters Into Licensing Agreement With Genedata For Genedata Expressionist 55

Maruishi Pharma to Acquire Five Injectable Brands from Ono Pharma 56

Ono Pharmaceutical Co Ltd, Key Competitors 57

Ono Pharmaceutical Co Ltd, Key Employees 58

Ono Pharmaceutical Co Ltd, Other Locations 59

Ono Pharmaceutical Co Ltd, Subsidiaries 60

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Ono Pharmaceutical Co Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.